4.6 Article

Matching of array CGH and gene expression microarray features for the purpose of integrative genomic analyses

Journal

BMC BIOINFORMATICS
Volume 13, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1471-2105-13-80

Keywords

-

Funding

  1. European Community's Seventh Framework Programme [FP7-269553]
  2. Center for Medical Systems Biology (CMSB)

Ask authors/readers for more resources

Background: An increasing number of genomic studies interrogating more than one molecular level is published. Bioinformatics follows biological practice, and recent years have seen a surge in methodology for the integrative analysis of genomic data. Often such analyses require knowledge of which elements of one platform link to those of another. Although important, many integrative analyses do not or insufficiently detail the matching of the platforms. Results: We describe, illustrate and discuss six matching procedures. They are implemented in the R-package sigaR (available from Bioconductor). The principles underlying the presented matching procedures are generic, and can be combined to form new matching approaches or be applied to the matching of other platforms. Illustration of the matching procedures on a variety of data sets reveals how the procedures differ in the use of the available data, and may even lead to different results for individual genes. Conclusions: Matching of data from multiple genomics platforms is an important preprocessing step for many integrative bioinformatic analysis, for which we present six generic procedures, both old and new. They have been implemented in the R-package sigaR, available from Bioconductor.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Oral cancer prediction by noninvasive genetic screening

Jos B. Poell, Leon J. Wils, Arjen Brink, Ralf Dietrich, Christine Krieg, Eunike Velleuer, Ilkay Evren, Elisabeth R. Brouns, Jan G. de Visscher, Elisabeth Bloemena, Bauke Ylstra, Ruud H. Brakenhoff

Summary: This study developed a noninvasive genetic assay to detect genetically altered fields in the oral cavity. The assay demonstrated high accuracy and predicted the development of oral squamous cell carcinoma in high-risk individuals. This method can be used for cancer screening in high-risk populations and to map the extent of lesions beyond what is visible.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Hematology

Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma

Jakoba J. Eertink, Gerben J. C. Zwezerijnen, Sanne E. Wiegers, Simone Pieplenbosch, Martine E. D. Chamuleau, Pieternella J. Lugtenburg, Daphne de Jong, Bauke Ylstra, Matias Mendeville, Ulrich Duehrsen, Christine Hanoun, Andreas Huettmann, Julia Richter, Wolfram Klapper, Yvonne W. S. Jauw, Otto S. Hoekstra, Henrica C. W. de Vet, Ronald Boellaard, Josee M. Zijlstra

Summary: This study investigated whether combining clinical, molecular genotype, and radiomics features can improve the outcome prediction of patients with aggressive B-cell lymphoma. The results showed that adding radiomics features improved the model performance and positive predictive values, aiding in the identification of poor prognosis patients.

BLOOD ADVANCES (2023)

Article Oncology

Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab

Sanne ten Hoorn, Linda Mol, Dirkje W. Sommeijer, Lisanne Nijman, Tom van den Bosch, Tim R. de Back, Bauke Ylstra, Erik van Dijk, Carel J. M. van Noesel, Roy J. Reinten, Iris D. Nagtegaal, Miriam Koopman, Cornelis J. A. Punt, Louis Vermeulen

Summary: We evaluated the potential efficacy of adding anti-EGFR therapy to anti-VEGF therapy in a subgroup of patients with metastatic colorectal cancer. The retrospective study (CAIRO2 trial, n = 736) showed no benefit of anti-EGFR addition within the subgroup, but an overall survival increase of 6.5 months compared to the original trial.

CLINICAL COLORECTAL CANCER (2023)

Article Oncology

Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell

G. Tjitske Los-de Vries, Phylicia Stathi, Ryanne Rutkens, Nathalie J. Hijmering, Jeroen A. C. W. Luijks, Patricia J. T. A. Groenen, Daphne de Jong, Bauke Ylstra, Margaretha G. M. Roemer

Summary: Primary and relapsed LBCL-IP have a common set of genetic alterations that support survival and proliferation, providing insight into the disease progression.

CANCER RESEARCH (2023)

Article Gastroenterology & Hepatology

Clonal Patterns Between Pouch Neoplasia and Prior Colorectal Neoplasia in Inflammatory Bowel Disease Patients: An Exploratory Cohort Study

Maarten te Groen, Lauranne A. A. P. Derikx, Lisa van Lierop, Bauke Ylstra, Frank Hoentjen, Iris D. Nagtegaal, Femke Simmer

Summary: The presence of previous colorectal neoplasia is the most significant indicator for the development of pouch neoplasia in inflammatory bowel disease. However, the underlying mechanism remains unknown. Our study found evidence of clonality between colorectal and pouch neoplasia in 30% of patients, suggesting that most pouch neoplasia develops independently from prior colorectal lesions.

INFLAMMATORY BOWEL DISEASES (2023)

Article Oncology

Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data

Leon Emanuel Schnoeller, Daniel Piehlmaier, Peter Weber, Nikko Brix, Daniel Felix Fleischmann, Alexander Edward Nieto, Martin Selmansberger, Theresa Heider, Julia Hess, Maximilian Niyazi, Claus Belka, Kirsten Lauber, Kristian Unger, Michael Orth

Summary: Despite previous efforts, glioblastoma remains a highly devastating disease with poor prognosis. In this study, we integrated data from multiple molecular levels to identify therapy resistance and potential targets for treatment. Our findings suggest new candidates for combination therapy and provide proof-of-concept for multi-level data integration. The generated dataset offers valuable resources for researchers in the field of glioblastoma therapy resistance.

RADIATION ONCOLOGY (2023)

Article Oncology

A Novel Subgroup of UCHL1-Related Cancers Is Associated with Genomic Instability and Sensitivity to DNA-Damaging Treatment

Sebastian Burkart, Christopher Weusthof, Karam Khorani, Sonja Steen, Fabian Stoegbauer, Kristian Unger, Julia Hess, Horst Zitzelsberger, Claus Belka, Ina Kurth, Jochen Hess

Summary: In this study, a new subgroup of UCHL1-related cancers was identified across multiple solid tumor entities and characterized by increased genomic instability and vulnerability to DNA-damaging treatment, with a favorable prognosis after radiotherapy. A novel classification model was established for accurate identification of UCHL1-related cancers, providing a basis for further research.

CANCERS (2023)

Article Oncology

False positivity in break apart fluorescence in-situ hybridization due to polyploidy

Anna Lena van Gulik, Ellen Sluydts, Liesbet Vervoort, Mark Kockx, Pim Kortman, Bauke Ylstra, Stephen P. Finn, Lukas Bubendorf, Idris Bahce, Daoud Sie, Teodora Radonic, Birgit Lissenberg-Witte, Erik Thunnissen

Summary: This study investigates the impact of cell size and ploidy on FISH results. The results show that in liver cell nuclei, the number of FISH signals increases with nuclear size and section thickness. In non-small cell lung cancer cases, tumor cells with higher ploidy levels and nuclear size have an increased chance of single signals. In addition, no rearrangements were found in lung cancer samples with borderline ALK FISH results, proving a false positive result.

TRANSLATIONAL LUNG CANCER RESEARCH (2023)

Letter Hematology

Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment

Wendy B. C. Stevens, G. Tjitske Los-de Vries, Carole Langois-Jacques, Andrew J. Clear, Phylicia Stathi, Birgitta Sander, Andreas Rosenwald, Maria Calaminici, Eva Hoster, Wolfgang Hiddemann, Philippe Gaulard, Gilles Salles, Wolfram Klapper, Luc Xerri, Catherine Burton, Reuben M. Tooze, Alexandra G. Smith, Christian Buske, David W. Scott, Yasodha Natkunam, Ranjana Advani, Laurie H. Sehn, John Raemaekers, John Gribben, Sandra Lockmer, Eva Kimby, Marie Jose Kersten, Delphine Maucort-Boulch, Bauke Ylstra, Erik van Dijk, Daphne de Jong

HEMASPHERE (2023)

Article Hematology

Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma

Patricia Johansson, Stefan Alig, Julia Richter, Christine Hanoun, Jan Rekowski, Jan Duerig, Bauke Ylstra, Daphne de Jong, Wolfram Klapper, Ash A. Alizadeh, Ulrich Duehrsen, Andreas Huettmann

Summary: In DLBCL, a positive interim PET scan predicts treatment failure, and combining it with the presence of an IgM gammopathy can improve prediction. The combination of interim PET and IgM gammopathy can dichotomize the population into high-risk and low-risk groups with significantly different outcomes. Only the interim PET result and IgM gammopathy status were significantly associated with outcome, making them important factors in risk-adapted treatment strategies.

ANNALS OF HEMATOLOGY (2023)

Editorial Material Hematology

DNA or RNA? Classification of B-cell lymphomas

Bauke Ylstra, Daphne de Jong

Summary: In this study, the authors demonstrate the usefulness of a dark zone signature (DZsig) for diagnosing aggressive B-cell lymphoma with DLBCL morphology, and highlight its strong prognostic value.

BLOOD (2023)

Article Pathology

Prognostic Value of T-Cell Density in the Tumor Center and Outer Margins in Gastric Cancer

Tanya T. D. Soeratram, Hedde D. Biesma, Jacqueline M. P. Egthuijsen, Elma Meershoek-Klein Kranenbarg, Henk H. Hartgrink, Cornelis J. H. van de Velde, Aart Mookhoek, Erik van Dijk, Yongsoo Kim, Bauke Ylstra, Hanneke W. M. van Laarhoven, Nicole C. T. van Grieken

Summary: Tumor-infiltrating lymphocytes are important for the survival of gastric cancer patients, and T-cell densities in different regions of the tumor can serve as prognostic markers. CD8OIM and FOXP3TC are identified as key factors for survival, and the combination of their densities can stratify patients into distinct subgroups with different prognosis. These immune subgroups are independent predictors for cancer-specific survival in resectable gastric cancer.

MODERN PATHOLOGY (2023)

Article Multidisciplinary Sciences

Multi-scale spatial modeling of immune cell distributions enables survival prediction in primary central nervous system lymphoma

Margaretha G. M. Roemer, Tim van de Brug, Erik Bosch, Daniella Berry, Nathalie Hijmering, Phylicia Stathi, Karin Weijers, Jeannette Doorduijn, Jacoline Bromberg, Mark van de Wiel, Bauke Ylstra, Daphne de Jong, Yongsoo Kim

Summary: In order to understand the clinical relevance of the tumor microenvironment (TME), it is important to study the interactions between malignant and non-malignant cells in clinical samples. Researchers have developed a computational framework to comprehensively analyze the spatial context of the TME, including close and long-distance interactions between different cell types. This framework was applied to imaging data from 88 primary central nervous system lymphomas, revealing significant prognostic subgroups mainly determined by the spatial context. The results highlight the importance of spatial context in predicting patient survival, particularly in relation to macrophage infiltration near specific cell types.

ISCIENCE (2023)

Letter Hematology

Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment

Esther E. E. Drees, Yvonne W. S. Jauw, Erik van Dijk, Sven Borchmann, Sandra A. W. M. Verkuijlen, Phylicia Stathi, Nils J. Groenewegen, Nathalie J. Hijmering, Daniella R. A. I. Berry, Eric J. Meershoek, Danielle Hoogmoed, Anne Kwakman, Tessa J. Molenaar, Dirk M. Pegtel, Bauke Ylstra, Daphne de Jong, Josee M. Zijlstra, Margaretha G. M. Roemer

HEMASPHERE (2022)

Article Hematology

Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV

G. Tjitske Los-deVries, Wendy B. C. Stevens, Erik van Dijk, Carole Langois-Jacques, Andrew J. Clear, Phylicia Stathi, Margaretha G. M. Roemer, Matias Mendeville, Nathalie J. Hijmering, Birgitta Sander, Andreas Rosenwald, Maria Calaminici, Eva Hoster, Wolfgang Hiddemann, Philippe Gaulard, Gilles Salles, Heike Horn, Wolfram Klapper, Luc Xerri, Catherine Burton, Reuben M. Tooze, Alexandra G. Smith, Christian Buske, David W. Scott, Yasodha Natkunam, Ranjana Advani, Laurie H. Sehn, John Raemaekers, John Gribben, Eva Kimby, Marie Jose Kersten, Delphine Maucort-Boulch, Bauke Ylstra, Daphne de Jong

Summary: The genomic and immune microenvironmental features of follicular lymphoma (FL) differ between stage I and stage III/IV, with distinct differences in cell populations and mutations. This exploratory study provides new insights into the heterogeneity of FL and its underlying oncogenic pathways.

BLOOD ADVANCES (2022)

No Data Available